Navigation Links
ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
Date:9/10/2007

5 (b)(2) NDA covering ANX-514, ADVENTRX must certify that all applicable Taxotere patents have expired prior to the manufacture, use or sale of ANX-514.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that preclinical and clinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical and clinical data suggests or as otherwise anticipated; difficulties or delays in developing, testing, manufacturing and marketing and obtaining regulatory approval for ANX-514, including receiving necessary regulatory approvals for clinical trials of ANX-514 and the potential for automatic injunctions regarding FDA approval of ANX-514 and other challenges by patent holders during the Section 505(b)(2) process; uncertainty under Section 505(b)(2) resulting from legal action against the FDA and the potential that future interpretations of Section 505(b)(2) could delay or prevent the FDA from app
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Nematicide is ... nematodes. Nematodes are microscopic parasitic roundworms, found in ... inside other plants and animals. Nematicides have tended ... other properties promoting migration through the soil. A ... 1,000 plant-parasitic nematodes. With more than 10,000 species ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration market ... and increased acceptance of new filtration technologies in end ... are also catalyzing the growth of laboratory filtration market. ... grow at a strong CAGR during the forecast period ... million by 2019. The market is mainly driven by ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research ... new genetic test built upon research from their published ... will provide physicians with an objective way to understand ... stratified between individuals. With this new test, physicians will ... genetic predisposition that will affect their pain tolerance. , ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... the level of each type of cholesterol carrier or ... the presence of excessive cholesterol levels in the body, ... precursor condition to heart attack and other cardiovascular disorders. ... worldwide, therefore testing for cholesterol levels on a regular ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... Inc. announced today the initiation of a Phase ... inhibitor CX-4945 in patients with multiple myeloma. Cylene ... million financing with participation from existing investors including ... Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. ...
... GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK, ... www.helixlife.com ), a private label distribution partnership serving the ... CEO, stated, "HelixLife gives GeneLink reach into new areas ... have not been available to us.  The HelixLife team ...
... and BRUSSELS, Sept. 24 Tarsa Therapeutics, Inc. ... UGNE ) today reported preclinical data showing ... with other drugs in reducing the collagen degradation ... at the 2010 Osteoarthritis Research Society International (OARSI) ...
Cached Biology Technology:Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 2Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 3GeneLink Announces HelixLife Private Label Distribution Agreement 2Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 2Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 3Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 4Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 5
(Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
(Date:9/30/2014)... exposure to tetrachloroethylene (PCE) in drinking water may ... according to a new study led by a ... The study, published in the journal Environmental ... unexposed pregnancies among 1,766 women in Cape Cod, ... 1960s to the early 1980s by the installation ...
(Date:9/30/2014)... England Journal of Medicine reports positive results of ... against the subset of lung cancer marked by rearrangement ... 50 patients with advanced non-small cell lung cancer testing ... 72 percent, with 3 complete responses and 33 partial ... for the disease to resume its growth after being ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Contaminated water linked to pregnancy complications, BU study finds 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... was only something that was necessary to keep your car ... and animals living in cold climates have natural antifreeze proteins ... matter. Without such antifreeze, living matter would suffer from frost ... proteins is one of the major evolutionary routes taken by ...
... a comprehensive, open-access collection of georeferenced biological information about ... refers to the visible-for-the-eye organisms that live near or ... sponges , ascidians , crustaceans . ... conservation activities on species living near the ocean bottom ...
... that has emerged in the Middle East is well-adapted to ... to a study to be published on February 19 in ... Society for Microbiology. The study indicates that the virus HCoV-EMC ... and evade the innate immune system as easily as a ...
Cached Biology News:Not just cars, but living organisms need antifreeze to survive 2Not just cars, but living organisms need antifreeze to survive 3Data paper describes Antarctic biodiversity data gathered by 90 expeditions since 1956 2Data paper describes Antarctic biodiversity data gathered by 90 expeditions since 1956 3Novel coronavirus well-adapted to humans, susceptible to immunotherapy 2Novel coronavirus well-adapted to humans, susceptible to immunotherapy 3
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: